Loading
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Latest quote
$19.31
+$0.215 · +1.13%
After-hours
$19.09
−$0.22 · -1.14%
Oct 8, 7:49 PM ET
Regular session · ET · Market data may be delayed.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Day range
Current $19.31
52-week range
Current $19.31
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
15
Overpriced
Sentiment
75
Bullish
Risk
55
Elevated Risk
Momentum
59
Neutral
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.
Day range
Current $19.31
52-week range
Current $19.31
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 6.94M USD | 9.04M USD | 14.02M USD | — | — |
| Cost of goods sold | 2.96M USD | — | — | — | — |
| Gross profit | 3.99M USD | 9.04M USD | 14.02M USD | — | — |
| Research and development | 174.33M USD | 129.54M USD | 23.09M USD | 23.27M USD | 14.11M USD |
| Selling, general, and administrative | 43.77M USD | 32.96M USD | 19.66M USD | 13.63M USD | 11.09M USD |
| Operating expenses | 218.1M USD | 314.84M USD | 123.55M USD | 36.9M USD | 25.2M USD |
| Interest income | 11.72M USD | 12.84M USD | 2.72M USD | 5K USD | 10K USD |
| Interest expense | — | — | — | 5K USD | 10K USD |
| Depreciation and amortization | 2.96M USD | 2.1M USD | 728K USD | 631K USD | 755K USD |
| Operating income | −214.11M USD | −305.8M USD | −109.53M USD | −36.9M USD | −25.2M USD |
| Net income | −212.39M USD | −292.96M USD | −106.81M USD | −36.9M USD | −24.71M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$33.00
70.90% upsideFunds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI88.66M0.00%2.3T USD0.03%$379.56-0.39%
iShares Russell 2000 ETFIWM52.88M0.07%78.56B USD0.19%$277.57-0.05%
State Street SPDR S&P Biotech ETFXBI38.29M0.38%10.08B USD0.35%$149.29-0.63%
Vanguard Extended Market ETFVXF33.93M0.03%95.4B USD0.05%$233.13-0.15%
iShares Russell 2000 Growth ETFIWO18.84M0.13%14.25B USD0.24%$353.47-0.53%
Vanguard Russell 2000 ETFVTWO16.61M0.09%18B USD0.06%$112.1-0.10%
Schwab U.S. Small-Cap ETFSCHA11.43M0.05%21.7B USD0.03%$32.66+0.15%
Vanguard Health Care ETFVHT8.06M0.04%22B USD0.09%$313.85-0.46%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
